Compare Nasdaq Inc (NDAQ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Nasdaq Inc trades at $94.7 (market cap $53.13B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: Nasdaq Inc pays a 1.22% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Nasdaq Inc nearer its low. Which is the better fit depends on your goals.
| NDAQ | XBI | |
|---|---|---|
Market Cap | $53.13B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $100.98 | $169.55 |
52-Week Low | $76.85 | $93.43 |
Enterprise Value | $59.58B | — |
Dividend Yield | 1.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq (NDAQ) trades at $95.04, down 1.9% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.07 exceeding the $0.984 estimate. Revenue grew to $8.26B in 2025, and net income margin improved to 22.52%. Recent news highlights strategic acquisitions like Dasseti to enhance AI capabilities.
The outlook is positive with a consensus price target of $109.20, implying 15% upside. Key opportunities include continued earnings growth and expansion in data-driven investment technology. Risks involve market volatility and execution of acquisition integration. Analyst sentiment is bullish with 61% buy ratings.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
